Company news

Foresee Pharmaceuticals Co., Ltd. news in 2025

Foresee Pharmaceuticals Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate

December 24, 2025

Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer

August 28, 2025